Slide WE’RE ON IT! APEIRON Biologic’s work on
a drug candidate against
COVID-19
more

APEIRON BIOLOGICS

Improving the life of our patients with next-generation technologies and individual therapies

  • Focused on novel cancer immunotherapies and respiratory treatments
  • First Austrian biotech company to develop a cancer immunotherapy product through to market
    Approval in 2017 of APN311 for treatment of pediatric neuroblastoma in EU and other countries,
    US/Japan BLA filing in preparation
  • Respiratory drug candidate APN01 in clinical development
  • Oncology pipeline in clinical stages
  • Lead by highly experienced and motivated team with global background

NEWS

SARS-CoV-2 and herd immunity – will the virus always be one step ahead ?
‘Herd immunity’ and vaccine strategy The concept of ‘herd immunity’ is massively important in terms of disease transmission and overall efficacy of vaccine strategies. It relies on a certain proportion of a population having immunity against a disease, thus protecting those who are unable to receive vaccines. If vaccinated individuals stop the spread of infection,...
April 14, 2021
APEIRON’s APN01 shows clinical benefits for severely ill COVID-19 patients in phase 2 trial
Treatment was safe and well tolerated and no drug-related severe adverse events were observed Significant improvement in mechanical ventilator-free Days and reduction in viral RNA load observed Biomarker development supports APN01’s mode of action against SARS-CoV-2 Investigators and experts recommend further development of APN01 in COVID-19 Press release (EN) | Presseaussendung (DE)
March 12, 2021
Reactivated immune cells of cancer patients (APN401) for the treatment of solid tumors
In light of the 21st annual #WorldCancerDay we would like to draw your attention to our work in fighting cancer. We at APEIRON Biologics AG want to make a contribution to people’s #wellbeing by developing the immune therapy APN401. APN401´s proprietary process brings in a paradigm change in cancer treatment to fight hematological and solid...
February 4, 2021